New User:

-or-
Username:
Password:
Forgot your password?
News Breaks
November 24, 2009
08:27 EDTSLXP
theflyonthewall.com: Salix target raised to $35 from $24 at Caris
Caris raised its estimates and target price for Salix due to a higher price point and increased penetration for the company's Xifaxan drug. The firm keeps a Buy rating on the stock. :theflyonthewall.com



News For SLXP From The Last 14 Days
Check below for free stories on SLXP the last two weeks.
There are 5 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing.
February 10, 2012
12:04 EDTSLXP
theflyonthewall.com: Salix weakness is a buying opportunity, says BofA/Merrill

Subscribe for More Information
:theflyonthewall.com
10:29 EDTSLXP
theflyonthewall.com: Salix weakness is a buying opportunity, says Caris
Caris said Salix is down on an FDA draft guidance report for Xifaxan generic requirements. The guidance requires generics only do a clinical study on 200mg for travelers diarrhea, not for 550mg, which is most of Salix's franchise. The firm recommends using Salix weakness as a buying opportunity. Reference Link :theflyonthewall.com

February 7, 2012
07:04 EDTSLXP
theflyonthewall.com: Salix announces FDA granting of priority review designation for Crofelemer
Salix Pharmaceuticals announced that the U.S. Food and Drug Administration has granted Priority Review designation for the company's New Drug Application for crofelemer 125 mg tablets for the proposed indication for the control and symptomatic relief of diarrhea in patients with human immunodeficiency virus/acquired immune deficiency syndrome on anti-retroviral therapy. :theflyonthewall.com

February 6, 2012
14:22 EDTSLXP
theflyonthewall.com: FDA posts approval of Salix's Giazo

Subscribe for More Information
:theflyonthewall.com

January 31, 2012
11:21 EDTSLXP
theflyonthewall.com: Piper Jaffray's biotech and specialty pharma analysts hold a conference call

Subscribe for More Information
:theflyonthewall.com